Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 15

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 15
---
View (“Merger Sub”), with and into Profusa, Inc. (“Profusa”), a California corporation (the “Merger”), with Profusa surviving the Merger as a wholly owned subsidiary of NorthView (the time that the Merger becomes effective being referred to as the “Effective Time”), pursuant to the terms of the Merger Agreement and Plan of Reorganization, dated as of November 7, 2022, by and among NorthView, Merger Sub and Profusa, as amended and attached to this proxy statement/prospectus as Annex A (as amended, the “Merger Agreement”), as more fully described elsewhere in this proxy statement/prospectus and (2) the other transactions contemplated by the Merger Agreement and documents related thereto (collectively, the “Business Combination”). As used in this proxy statement/prospectus, “New Profusa” refers to NorthView after giving effect to the Business Combination. Pursuant to the Merger Agreement, immediately prior to the Effective Time (as defined in this proxy statement/prospectus), each share of issued and outstanding Profusa preferred stock, par value $0.01, shall be converted into a number of shares of Profusa common stock, par value $0.01 (“Profusa Common Stock”). At the effective time of the Merger, (i) each share of issued and outstanding Profusa Common Stock shall be converted into a number of shares of New Profusa common stock, par value $0.0001 (“New Profusa Common Stock”), based on the Exchange Ratio described below, (ii) each option to purchase Profusa Common Stock shall be converted into an option to purchase New Profusa Common Stock at the Exchange Ratio, and (iii) each warrant to purchase Profusa Common Stock shall be converted into a warrant to purchase New Profusa Common Stock at the Warrant Ratio (as defined in the Merger Agreement). Following the entry into Amendment No. 4 to the Merger Agreement (as defined above), the aggregate consideration to be received by the Profusa shareholders is based on the sum of (a) the pre -transactionequity value of $155,000,000, plus (b) the Incentive Equity Value (which is expected to be $29,018,330 for purposes of this proxy statement/prospectus), plus (c) the Private Placement Value (which is expected to be $14,867,899 for purposes of this proxy statement/prospectus), plus (d) the Aggregate Exercise Price, minus (